Target Audience
The design of this program addresses the needs of rheumatology clinicians and other specialists involved in the care of patients with systemic lupus erythematosus (SLE).
Program Description
Despite the plethora of investigational agents to treat SLE that have been studied extensively in clinical trials over the last several decades, very few therapies have ever become available to treat this complex, heterogeneous disease. However, 2021 ushered in US Food and Drug Administration (FDA) approvals for a novel targeted therapy to treat SLE and 2 options for treating lupus nephritis. At the same time, researchers and clinicians have been fervently working to improve disease assessment strategies and set realistic treatment goals for patients with SLE. As new approaches to disease assessment and targeted therapies in SLE become available, optimization of the day-to-day management of SLE must continue to evolve. In this Point-of-Care 101™ Microlearning Series, 2 expert rheumatologists will provide focused education on comprehensive patient evaluation, clinical profiles of currently available biologic therapies, and best practices for individualizing disease management in patients with SLE. Utilizing a multimedia delivery format that combines text and video, this educational series meets the needs of busy clinician learners who wish to stay current on the evolving best practices in managing patients with SLE.
Modules
Module 1: Evaluating the Patient With SLE
Module 2: Real-world Strategies for Managing Moderate-to-Severe SLE
Module 3: Targeted Treatment Options for SLE
Patient Perspective Videos
Be sure to visit the Clinical Resource Center or the ExchangeCME channel on YouTube to view two informative videos providing the SLE patient's perspective.


Evaluating the Patient with SLE


Real-World Strategies for Managing Moderate-to-Severe SLE


Targeted Treatment Options for SLE
